Bristol Myers Squibb (CELG-RI) Cash & Current Investments (2009 - 2026)

Bristol Myers Squibb (CELG-RI) has 18 years of Cash & Current Investments data on file, last reported at $10.5 billion in Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $10.5 billion, down 11.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $10.5 billion (down 11.0% YoY), and the FY2025 annual result was $10.7 billion, down 1.71% from the prior year.
• Cash & Current Investments retreated to $10.5 billion in Q1 2026 per CELG-RI's latest filing, from $10.7 billion in the prior quarter.
• Over five years, Cash & Current Investments peaked at $16.5 billion in Q3 2025 and troughed at $6.7 billion in Q2 2024.
• A 5-year average of $10.8 billion and a median of $10.5 billion in 2026 frame the typical range for Cash & Current Investments.
• The sharpest annual moves came in 2022 and 2025: Cash & Current Investments slumped 45.46% in 2022, then surged 104.46% in 2025.
• A 5-year view of Cash & Current Investments shows it stood at $9.3 billion in 2022, then surged by 32.71% to $12.3 billion in 2023, then slipped by 11.57% to $10.9 billion in 2024, then declined by 1.71% to $10.7 billion in 2025, then declined by 1.75% to $10.5 billion in 2026.
• Business Quant data shows CELG-RI's Cash & Current Investments at $10.5 billion in Q1 2026, $10.7 billion in Q4 2025, and $16.5 billion in Q3 2025.